Tools
Stock profile

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

ALNY · Latest close $149.40 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$149.40
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
2 / 1
vs previous quarter
Trimmed / exited
1
vs previous quarter

ALNYLAM PHARMACEUTICALS, INC. (ALNY) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 1 fund adding, and 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($543.1K bought vs $398.9K sold). 0 members of Congress reported 0 purchases vs 1 sale. Latest close $149.40 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $144.3K
Congress
0 buys vs 1 sale
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Deep Track Capital · Paradigm Biocapital Advisors · Dodge & Cox Funds — 5 tracked funds hold ALNY. See all holders.

Insider and Congress activity

Insiders bought on the open market (2 purchases, $543.1K) vs 1 sale ($398.9K). Latest buy: Nov 10, 2026. Insider trading 0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading

Often held alongside

MBX BIOSCIENCES INC (MBX) · GENMAB A/S (GMAB) · TARSUS PHARMACEUTICALS INC (TARS) · VERA THERAPEUTICS INC (VERA) · BELITE BIO, INC (BLTE) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Deep Track Capital3.61%825,000NEW Q3 filed Nov 16
Paradigm Biocapital Advisors2.71%480,000NEW Q3 filed Nov 16
Dodge & Cox Funds0.31%1,955,393ADDED (+1.4%) Q3 filed Nov 13
Deerfield Management0.21%67,935HELD Q3 filed Nov 16
OrbiMed Advisors0.09%17,000TRIMMED (-85.7%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -48.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

491.22135.732024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding788 of 8,857 filers
Long-only filers among them783
Change vs 2026 Q1+12 net · 711 entered · 699 exited
Shares reported, all filers132,604,323
Reported value, all filers$38.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$3.7B
Net income · FY2025$313.7M
Total assets · FY2025$5.0B
Shares outstanding133,937,576
Market cap (at latest close)$20.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 23, 2026.

Short interest

Shares short · Oct 15, 20266,568,786
Share of shares outstanding4.90%
Days to cover5.10

Shares short at recent settlements — Jul 31, 2026: 4.8M · Aug 14, 2026: 4.8M · Aug 31, 2026: 6.3M · Sep 15, 2026: 7.2M · Sep 30, 2026: 7.7M · Oct 15, 2026: 6.6M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 23, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 65 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 159 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 23, 2026.

Insider trading · Form 4

2 insiders bought on the open market in the last 90 days (2 purchases, $543.1K), against 1 sale by 1 insider ($398.9K). Latest buy: Nov 10, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Sigal Charles Elliott · 1,600 shares on Nov 10, 2026 · filed Nov 12, 2026$152.25-5.2% (close Nov 13, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Nov 13, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 10, 2026Sigal Charles ElliottBuy1,600$152.25$243.6KSEC filing
Nov 9, 2026SCHULMAN AMY WBuy1,910$156.82$299.5KSEC filing
Oct 2, 2026SUPRAN BRYANEVP, CLO and SecretarySell1,758$226.88$398.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 2, 2026SUPRAN BRYANOfficer1,758$398.9KOct 2, 2026SEC filing
Jun 1, 2026PYOTT DAVID E IDirector3,830$1.1MJun 1, 2026SEC filing
Apr 6, 2026McLaughlin MelissaOfficer2,286$731.7KApr 6, 2026SEC filing
Mar 5, 2026Fitzgerald Kevin JosephOfficer658$213.0KMar 5, 2026SEC filing
Mar 5, 2026Garg PushkalOfficer2,404$778.2KMar 5, 2026SEC filing
Mar 3, 2026Fitzgerald Kevin JosephOfficer1,652$530.9KMar 3, 2026SEC filing
Mar 3, 2026Garg PushkalOfficer1,775$570.4KMar 3, 2026SEC filing
Feb 27, 2026Garg PushkalOfficer4,627$1.5MFeb 27, 2026SEC filing
Feb 17, 2026Fitzgerald Kevin JosephOfficer2,041$677.5KFeb 17, 2026SEC filing
Jan 13, 2026Fitzgerald Kevin JosephOfficer2,290$845.2KJan 13, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 14, 2026Capital World InvestorsSC 13G/A10,916,7998.2%Mar 31, 2026SEC filing
May 14, 2026Capital Research Global InvestorsSC 13G/A9,471,1817.1%Mar 31, 2026SEC filing
May 6, 2026FMR LLCSC 13G/A14,640,524.8711.0%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G7,104,5365.3%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Nov 5, 2025FMR LLCSC 13G/A16,834,094.7412.8%Sep 30, 2025SEC filing
Apr 7, 2025The Vanguard GroupSC 13G/A13,056,60510.0%Mar 31, 2025SEC filing
Feb 13, 2025Capital Research Global InvestorsSC 13G6,968,5135.4%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 1 sale).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Booker, CorySenateD01Aug 11, 2026$1,001 - 15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 243 Lobbying Disclosure Act filings named this company as client, 2004–2026; most common issues: Medicare/Medicaid (158), Health Issues (71), Copyright/Patent/Trademark (30).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

Financial Screens

· Growth — Revenue up every year for 5 straight years

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Growth — Latest revenue: $3.7B · 5-yr revenue CAGR: 49.8% · Straight growth years: 7

· Insider Net Buying — Buy txns: 2 · Sell txns: 1 · Buy value: $543.1K · Latest buy: Nov 10, 2026

· Distress Risk (Altman Z″) — Z″-Score: -0.11 · Working capital / assets: 0.52 · Retained earnings / assets: -1.35 · EBIT / assets: 0.10 · Equity / liabilities: 0.19

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q1, ranked #47 of 50.

Also held by the tracked funds that hold ALNY — ranked by lift, the co-holding pattern described in Methodology: MBX BIOSCIENCES INC (MBX) · GENMAB A/S (GMAB) · TARSUS PHARMACEUTICALS INC (TARS) · VERA THERAPEUTICS INC (VERA) · BELITE BIO, INC (BLTE) · COGENT BIOSCIENCES INC (COGT) · TYRA BIOSCIENCES INC (TYRA) · STRUCTURE THERAPEUTICS INC (GPCR).

Recent 8-K filings

FiledItemsSource
Nov 5, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other EventsSEC filing
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 30, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

MBX BIOSCIENCES INC (MBX) · Track Record: how the signals scored · Practice timing on ALNY

One email a week: the week’s new filings and research. Subscribe free

← ALNT  ·  ALRM →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.